When more than 30,000 registrants gathered at the San Diego Convention Center for the Society for Neuroscience annual meeting November 12-16, they exchanged their latest data on the basic science on Alzheimer’s disease. Topics ran the gamut from protein propagation and inflammation to the hunt for plasma biomarkers and potential therapeutics. Alzforum reporter Madolyn Rogers brings you highlights.
Researchers at SfN 2016 painted a more detailed picture of how misfolded proteins may proliferate, as one cell spreads these “hot potatoes” to the next.
Researchers at SfN 2016 touted the advantages of APP knock-ins, but noted they are less useful than overexpression models for studying behavior.
At SfN 2016, researchers debuted new mouse models that may better represent human disease.
Researchers at SfN 2016 proposed dialing up the immune response in Alzheimer’s brains to enhance phagocytosis.
Researchers at SfN 2016 reported that oligomeric and exosomal forms in plasma predict AD as early as a decade prior to symptoms.
Scientists at SfN presented innovative ways to slow amyloid accumulation and preserve synapses.
Sanofi Genzyme will test a compound currently in development for Gaucher’s disease in Parkinson’s patients who carry a glucocerebrosidase (GBA) mutation.